


AMENDMENTS TO THE CLAIMS:


This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (previously presented) A pharmaceutical composition comprising an effective amount of a compound chosen from the compounds of general formulae I and Ia below for treating, by virtue of their cytotoxic properties, cancerous tumors and their metastases:



Formula I



Formula Ia

in which:

- X is chosen from oxygen,
- R₁ is chosen from hydrogen, halogens, a nitro group and groups -NR₈R₉ in which R₈ and R₉ are chosen, independently of each other, from hydrogen and (C₁-C₄) alkyl groups,
- R₂ is chosen from hydrogen and halogens,
- R₃ is chosen from halogens, (C₁-C₄) alkyl groups, (C₁-C₆) alkoxy groups, a guanidino group, groups -NR₁₀R₁₁ in which R₁₀ and R₁₁ are chosen, independently of each other, from hydrogen, (C₁-C₄) alkyl groups, (C₁-C₄) phenylalkyl groups and

groups $-(CH_2)_n-Y$ with Y being chosen from halogens and CN, $-CH(O-Et)_2$, (C_1-C_6) alkoxy, $-O-(CH_2)_2-N(CH_3)_2$ and $-N(CH_3)_2$ groups and $n = 1$ to 3 ,

- R_4 is chosen from hydrogen, halogens, nitro groups and groups $-NR_{12}R_{13}$ in which R_{12} and R_{13} are chosen, independently of each other, from hydrogen and (C_1-C_4) alkyl groups,


- R_5 , R_6 and R_7 are chosen from:

hydrogen or a halogen atom,

C_1-C_6 alkyl, hydroxyl, C_1-C_6 alkoxy, (C_1-C_6) alkoxy(C_1-C_6)alkyl, (C_1-C_4) alkylcarbonyloxy(C_1-C_4)alkyl, $-CHO$, $-COOH$, $-CN$, $-CO_2R_{14}$, $-CONHR_{14}$ and $-CONR_{14}R_{15}$ groups, $-NHCOR_{14}$ and $-NR_{14}R_{15}$ in which R_{14} and R_{15} are chosen, independently of each other, from hydrogen and (C_1-C_6) alkyl, $-phenyl-CO-CH_3$ and $-CH_2-CH_2-N(CH_3)_2$ groups,

$-phenyl-CO-CH_3$ or $-phenyl-CO-CH=CH-N(CH_3)_2$, morpholino, nitro or SO_3H groups,

groups:



R_{16} and R_{17} being chosen from C_1-C_6 alkyl groups and Ar being a C_6-C_{14} aryl group,


and with the exclusion of the compound formula Ia containing the combination $X = O$ and $R_1, R_2, R_3, R_4, R_5, R_6, R_7 = H$,

and the addition salts of these compounds with pharmaceutically acceptable acids.

2. (currently amended) A pharmaceutical composition comprising an effective amount of a compound chosen from the compounds of formula I in which:

- X is chosen from oxygen,
- R₁ is chosen from hydrogen, halogens, a nitro group and groups -NR₈R₉ in which R₈ and R₉ are chosen, independently of each other, from hydrogen and (C₁-C₄) alkyl groups,
- R₂ is chosen from hydrogen and halogens,
- R₃ is chosen from halogens, (C₁-C₄) alkyl groups, (C₁-C₆) alkoxy groups, a guanidino group, groups -NR₁₀R₁₁ in which R₁₀ and R₁₁ are chosen, independently of each other, from hydrogen, (C₁-C₄) alkyl groups, (C₁-C₄) phenylalkyl, -(CH₂)₂-N(CH₃)₂, and -(CH₂)₂-O-(CH₂)₂-N(CH₃)₂ groups,
- R₄ is chosen from hydrogen, halogens, nitro groups and groups -NR₁₂R₁₃ in which R₁₂ and R₁₃ are chosen, independently of each other, from hydrogen and (C₁-C₄) alkyl groups,
- R₅, R₆ and R₇ are chosen from:
 - hydrogen or a halogen atom,
 - C₁-C₆ alkyl, hydroxyl, C₁-C₆ alkoxy, -CHO, -COOH, -CN, -CO₂R₁₄, -CONHR₁₄ and -CONR₁₄R₁₅ groups, -NHCOR₁₄ and -NR₁₄R₁₅ groups in which R₁₄ and R₁₅ are chosen, independently of each other, from hydrogen and (C₁-C₆) alkyl and -CH₂-CH₂-N(CH₃)₂ groups,

-phenyl-CO-CH₃ or -phenyl-CO-CH=CH-N(CH₃)₂,
morpholino, nitro or SO₃H groups,
groups:



R₁₆ and R₁₇ being chosen from C₁-C₆ alkyl groups and Ar being a C₆-C₁₄ aryl group,

and [[the]] wherein addition salts of these compounds present with pharmaceutically acceptable acids in said pharmaceutical composition.

3. (previously presented) The pharmaceutical composition as claimed in claim 2, comprising an effective amount of a compound chosen from the compounds of formula I in which:

- X represents oxygen,
- R₁ is chosen from hydrogen and an amino group,
- R₂ is chosen from hydrogen and halogens,
- R₃ is chosen from halogens, (C₁-C₄) alkyl groups, (C₁-C₆) alkoxy groups, a guanidino group, groups -NR₁₀R₁₁ in which R₁₀ and R₁₁ are chosen, independently of each other, from hydrogen, methyl groups, (C₁-C₄) phenylalkyl, -(CH₂)₂-N(CH₃)₂, -(CH₂)₂-O-(CH₂)₂-N(CH₃)₂ groups,
- R₄ is chosen from hydrogen, halogens and nitro and amino groups,
- R₅, R₆ and R₇ represent a hydrogen,

and the addition salts of these compounds with pharmaceutically acceptable acids.

4. (previously presented) The pharmaceutical composition as claimed in claim 1, comprising an effective amount of a compound chosen from the compounds of formulae I and Ia in which:

- X represents oxygen,
- R₁ is chosen from hydrogen and an amino group,
- R₂ is chosen from hydrogen and halogens,
- R₃ is chosen from halogens, (C₁-C₄) alkyl groups, (C₁-C₆) alkoxy groups, a guanidino group, groups -NR₁₀R₁₁ in which R₁₀ and R₁₁ are chosen, independently of each other, from hydrogen, methyl groups, (C₁-C₄) phenylalkyl groups and groups -(CH₂)_n-Y with Y being chosen from halogens and groups CN, -CH(O-Et)₂, (C₁-C₆) alkoxy, -O-(CH₂)₂-N(CH₃)₂ and -N(CH₃)₂ and n = 1 to 3,
- R₄ is chosen from hydrogen, halogens, and nitro and amino groups,
- R₅ is chosen from a hydrogen, a halogen and a methoxy group,
- R₆ and R₇ are chosen from hydrogen and C₁-C₆ alkoxy, (C₁-C₆) alkoxy(C₁-C₆) alkyl and -CH₂OCOCH₃ groups, with the exclusion of the compound of formula Ia in which R₁, R₂, R₃, R₄, R₅, R₆, R₇ = H,

and the addition salts of these compounds with pharmaceutically acceptable acids.

5. (previously presented) The composition as claimed in claim 4, in which the compounds are chosen from:

5-(dimethylamino)-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-(benzylamino)-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-bromo-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-amino-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-methyl-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-methoxy-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-chloro-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-bromo-10-methoxy-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-(dimethylamino-2-ethyl)amino-9H-quino[4,3,2-de]-[1,10]phenanthrolin-9-one,

5-bis(2-chloroethyl)amino-9H-quino[4,3,2-de]-[1,10]phenanthrolin-9-one,

5-(2-chloroethyl)amino-9H-quino[4,3,2-de][1,10]-phenanthrolin-9-one,

4-bromo-5-amino-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,

5-bromo-9H-quino[4,3,2-de][1,7]phenanthrolin-9-one,

5-amino-9H-quino[4,3,2-de][1,7]phenanthrolin-9-one,

5-(dimethylamino-2-ethyl)amino-9H-quino[4,3,2-de][1,7]phenanthrolin-9-one,

5-bis(chloroethylamino-2-ethyl)amino-9H-quino[4,3,2-de][1,7]phenanthrolin-9-one,

5-(chloroethylamino-2-ethyl)amino-9H-quino[4,3,2-de][1,7]phenanthrolin-9-one,
4-bromo-5-amino-9H-quino[4,3,2-de][1,7]phenanthrolin-9-one,
and the addition salts thereof with pharmaceutically acceptable acids.



6. (cancelled)

7. (previously presented) The process according to claim 12, wherein said compound is selected from the group consisting of:

5-(dimethylamino)-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,
5-(benzylamino)-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,
5-bromo-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,
5-amino-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,
5-methyl-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,
5-methoxy-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,
5-chloro-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,
5-bromo-10-methoxy-9H-quino[4,3,2-de][1,10]phenanthrolin-9-one,
5-(dimethylamino-2-ethyl)amino-9H-quino[4,3,2-de]-[1,10]phenanthrolin-9-one,
5-bis(2-chloroethyl)amino-9H-quino[4,3,2-de]-[1,10]phenanthrolin-9-one,
5-(2-chloroethyl)amino-9H-quino[4,3,2-de][1,10]-phenanthrolin-9-one,

4-bromo-5-amino-9-H-quino[4,3,2-de][1,10]phenanthrolin-9-one,
5-bromo-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,
5-amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,
5-(dimethylamino-2-ethyl)amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,
5-bis(chloroethylamino-2-ethyl)amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,
5-(chloroethylamino-2-ethyl)amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,
4-bromo-5-amino-9-H-quino[4,3,2-de][1,7]phenanthrolin-9-one,
and the addition salts thereof with pharmaceutically acceptable acids.

8. (currently amended) Compounds of general formulae I and Ia



in which:

- X is chosen from oxygen,
- R₁ is chosen from hydrogen, halogens, a nitro group and groups -NR₈R₉ in which R₈ and R₉ are chosen,

independently of each other, from hydrogen and (C₁-C₄) alkyl groups,

- R₂ is chosen from hydrogen and halogens,
- R₃ is chosen from halogens, (C₁-C₄) alkyl groups, (C₁-C₆) ~~alkoxy groups~~, a guanidino group, groups -NR₁₀R₁₁ in which R₁₀ and R₁₁ are chosen, independently of each other, from hydrogen, (C₁-C₄) alkyl groups, (C₁-C₄) phenylalkyl groups and groups -(CH₂)_n-Y with Y being chosen from halogens and CN, -CH(O-Et)₂, (C₁-C₆) alkoxy, -O-(CH₂)₂-N(CH₃)₂ and -N(CH₃)₂ groups and n = 1 to 3,

- R₄ is chosen from hydrogen, halogens, nitro groups and groups -NR₁₂R₁₃ in which R₁₂ and R₁₃ are chosen, independently of each other, from hydrogen and (C₁-C₄) alkyl groups,

- R₅, R₆ and R₇ are chosen from:


- hydrogen or a halogen atom,

- C₁-C₆ alkyl, hydroxyl, C₁-C₆ alkoxy, (C₁-C₆) alkoxy(C₁-C₆) alkyl, (C₁-C₄) alkylcarbonyloxy(C₁-C₄) alkyl, -CHO, -COOH, -CN, -CO₂R₁₄, -CONHR₁₄ and -CONR₁₄R₁₅ groups, -NHCOR₁₄ and -NR₁₄R₁₅ in which R₁₄ and R₁₅ are chosen, independently of each other, from hydrogen and (C₁-C₆) alkyl, -phenyl-CO-CH₃ and -CH₂-CH₂-N(CH₃)₂ groups,

- phenyl-CO-CH₃ or -phenyl-CO-CH=CH-N(CH₃)₂,

- morpholino, nitro or SO₃H groups,

- groups:



R_{16} and R_{17} being chosen from C_1-C_6 alkyl groups and Ar being a C_6-C_{14} aryl group,

with the exclusion of the compounds of formula I in which $X = O$, and, or $R_1, R_2, R_4, R_5, R_6, R_7 = H$ and $R_3 = OCH_3$,

and with the exclusion of the compound formula Ia in which $X = O$ and $R_1, R_2, R_3, R_4, R_5, R_6, R_7 = H$,

and the addition salts of these compounds with pharmaceutically acceptable acids.

9. (currently amended) Compounds as claimed in claim 8, of formula I in which:

- X is chosen from oxygen,
- R_1 is chosen from hydrogen, halogens, a nitro group and groups $-\text{NR}_8\text{R}_9$ in which R_8 and R_9 are chosen, independently of each other, from hydrogen and (C_1-C_4) alkyl groups,
- R_2 is chosen from hydrogen and halogens,
- R_3 is chosen from halogens, (C_1-C_4) alkyl groups, ~~(C_1-C_6) alkoxy groups~~, a guanidino group, groups $-\text{NR}_{10}\text{R}_{11}$ in which R_{10} and R_{11} are chosen, independently of each other, from hydrogen, (C_1-C_4) alkyl groups, (C_1-C_4) phenylalkyl, $-(\text{CH}_2)_2-\text{N}(\text{CH}_3)_2$, and $-(\text{CH}_2)_2-\text{O}-(\text{CH}_2)_2-\text{N}(\text{CH}_3)_2$ groups,

- R_4 is chosen from hydrogen, halogens, nitro groups and groups $-NR_{12}R_{13}$ in which R_{12} and R_{13} are chosen, independently of each other, from hydrogen and (C_1-C_4) alkyl groups,

- R_5 , R_6 and R_7 are chosen from:


hydrogen or a halogen atom,

C_1-C_6 alkyl, hydroxyl, C_1-C_6 alkoxy, $-CHO$, $-COOH$, $-CN$, $-CO_2R_{14}$, $-CONHR_{14}$ and $-CONR_{14}R_{15}$ groups, $-NHCOR_{14}$ and $-NR_{14}R_{15}$ in which R_{14} and R_{15} are chosen, independently of each other, from hydrogen and (C_1-C_6) alkyl and $-CH_2-CH_2-N(CH_3)_2$ groups,

$-phenyl-CO-CH_3$ or $-phenyl-CO-CH=CH-N(CH_3)_2$,

morpholino, nitro or SO_3H groups,

groups:



R_{16} and R_{17} being chosen from C_1-C_6 alkyl groups and Ar being a C_6-C_{14} aryl group,

with the exclusion of the compounds in which $X = O$,
[[and,]]

and the addition salts thereof with pharmaceutically acceptable acids.

10. (previously presented) Compounds as claimed in claim 8, which are:


5-(dimethylamino)-9*H*-quino[4,3,2-*d*e][1,10]phenanthrolin-9-one,

5-(benzylamino)-9*H*-quino[4,3,2-de][1,10]phenanthrolin-9-one,
5-bromo-9*H*-quino[4,3,2-de][1,10]phenanthrolin-9-one,
5-amino-9*H*-quino[4,3,2-de][1,10]phenanthrolin-9-one,
5-methyl-9*H*-quino[4,3,2-de][1,10]phenanthrolin-9-one,
5-chloro-9*H*-quino[4,3,2-de][1,10]phenanthrolin-9-one,
5-bromo-10-methoxy-9*H*-quino[4,3,2-de][1,10]phenanthrolin-9-one,
5-(dimethylamino-2-ethyl)amino-9*H*-quino[4,3,2-de][1,10]-phenanthrolin-9-one,
5-bis(2-chloroethyl)amino-9*H*-quino[4,3,2-de][1,10]phenanthrolin-9-one,
5-(2-chloroethyl)amino-9*H*-quino[4,3,2-de][1,10]phenanthrolin-9-one,
4-bromo-5-amino-9-*H*-quino[4,3,2-de][1,10]phenanthrolin-9-one,
5-bromo-9-*H*-quino[4,3,2-de][1,7]phenanthrolin-9-one,
5-amino-9-*H*-quino[4,3,2-de][1,7]phenanthrolin-9-one,
5-(dimethylamino-2-ethyl)amino-9-*H*-quino[4,3,2-de]-[1,7]phenanthrolin-9-one,
5-bis(chloroethylamino-2-ethyl)amino-9-*H*-quino[4,3,2-de]-[1,7]phenanthrolin-9-one,
5-(chloroethylamino-2-ethyl)amino-9-*H*-quino[4,3,2-de]-[1,7]phenanthrolin-9-one,
4-bromo-5-amino-9-*H*-quino[4,3,2-de][1,7]phenanthrolin-9-one,
and the addition salts thereof with pharmaceutically acceptable acids.

11. (previously presented) A process for preparing a compound of formula Ia, in which:

- X is chosen from oxygen,
- R₁ is chosen from hydrogen, halogens, a nitro group and groups -NR₈R₉ in which R₈ and R₉ are chosen, independently of each other, from hydrogen and (C₁-C₄) alkyl groups,
- R₂ is chosen from hydrogen and halogens,
- R₃ is chosen from halogens, (C₁-C₄) alkyl groups, (C₁-C₆) alkoxy groups, a guanidino group, groups -NR₁₀R₁₁ in which R₁₀ and R₁₁ are chosen, independently of each other, from hydrogen, (C₁-C₄) alkyl groups, (C₁-C₄) phenylalkyl groups and groups -(CH₂)_n-Y with Y being chosen from halogens and CN, -CH(O-Et)₂, (C₁-C₆) alkoxy, -O-(CH₂)₂-N(CH₃)₂ and -N(CH₃)₂ groups and n = 1 to 3,
- R₄ is chosen from hydrogen, halogens, nitro groups and groups -NR₁₂R₁₃ in which R₁₂ and R₁₃ are chosen, independently of each other, from hydrogen and (C₁-C₄) alkyl groups,
- R₅, R₆ and R₇ are chosen from:
 - hydrogen or a halogen atom,
 - C₁-C₆ alkyl, hydroxyl, C₁-C₆ alkoxy, (C₁-C₆) alkoxy(C₁-C₆) alkyl, (C₁-C₄) alkylcarbonyloxy(C₁-C₄) alkyl, -CHO, -COOH, -CN, -CO₂R₁₄, -CONHR₁₄ and -CONR₁₄R₁₅ groups, -NHCOR₁₄ and -NR₁₄R₁₅ in which R₁₄ and R₁₅ are chosen, independently of each other, from hydrogen and (C₁-C₆) alkyl, -phenyl-CO-CH₃ and -CH₂-CH₂-N(CH₃)₂ groups,


-phenyl-CO-CH₃ or -phenyl-CO-CH=CH-N(CH₃)₂,
morpholino, nitro or SO₃H groups,
groups:




R₁₆ and R₁₇ being chosen from C₁-C₆ alkyl groups and Ar being a C₆-C₁₄ aryl group,

which consists in:


a - condensing a chlorobenzoic acid of formula:




with a dimethoxyaniline of formula:




to give a compound of formula IIa:




b - cyclizing the compound of formula IIa to give a compound of formula:




c - converting the compound into a quinone of formula IIIa:



d - reacting the quinone of formula IIIa with an azadiene of formula:



to give a compound of formula IVa:




e - reacting the compound of the formula IVa with dimethylformamide diethyl acetal to give the compound of formula Ia,

f - and, optionally, converting the compound thus obtained into another compound of formula Ia.

12. (previously presented) A process for inhibiting a tumor in a patient comprising administering an effective amount of a compound as defined in claim 1 to said patient.

13. (previously presented) A process for preparing compounds of general formula I, of formula:



in which:

- R_1 is chosen from hydrogen, halogens, a nitro group and groups $-NR_8R_9$ in which R_8 and R_9 are chosen, independently of each other, from hydrogen and (C_1-C_4) alkyl groups,

- R_2 is chosen from hydrogen and halogens,

- R_3 is chosen from halogens, (C_1-C_4) alkyl groups, (C_1-C_6) alkoxy groups, a guanidino group, groups $-NR_{10}R_{11}$ in which R_{10} and R_{11} are chosen, independently of each other, from hydrogen, (C_1-C_4) alkyl groups, (C_1-C_4) phenylalkyl groups and groups $-(CH_2)_n-Y$ with Y being chosen from halogens and CN, $-CH(O-Et)_2$, (C_1-C_6) alkoxy, $-O-(CH_2)_2-N(CH_3)_2$ groups and $-N(CH_3)_2$ and $n = 1$ to 3 ,

- R_4 is chosen from hydrogen, halogens, nitro groups and groups $-NR_{12}R_{13}$ in which R_{12} and R_{13} are chosen, independently of each other, from hydrogen and (C_1-C_4) alkyl groups,


- R_5 , R_6 and R_7 are chosen from:

hydrogen or a halogen atom,

C_1-C_6 alkyl, hydroxyl, C_1-C_6 alkoxy, (C_1-C_6) alkoxy (C_1-C_6) alkyl, (C_1-C_4) alkylcarbonyloxy (C_1-C_4) alkyl,

-CHO, -COOH, -CN, -CO₂R₁₄, -CONHR₁₄ and -CONR₁₄R₁₅ groups, -NHCOR₁₄ and -NR₁₄R₁₅ in which R₁₄ and R₁₅ are chosen, independently of each other, from hydrogen and (C₁-C₆) alkyl, -phenyl-CO-CH₃ and -CH₂-CH₂-N(CH₃)₂ groups,


-phenyl-CO-CH₃ or -phenyl-CO-CH=CH-N(CH₃)₂,
morpholino, nitro or SO₃H groups,
groups:




R₁₆ and R₁₇ being chosen from C₁-C₆ alkyl groups and Ar being a C₆-C₁₄ aryl group,

with the exclusion of the compounds of formula I in which R₁, R₂, R₄, R₅, R₆, R₇ = H and R₃ = OCH₃, which consists


a) in reacting a hydroquinone of formula




with a compound of formula




in the presence of $\text{CeCl}_3 \cdot 7\text{H}_2\text{O}$ and ethanol to give a compound of formula II



b) in converting the compound of formula II into a compound of formula III in the presence of H_2SO_4 in reflux acetic acid,




c) in reacting the compound of the formula III with $\text{HC}(\text{OC}_2\text{H}_5)_2\text{N}(\text{CH}_3)_2$ in DMF at 120°C to form a compound of formula IV



- d) in cyclizing the compound of formula IV to a compound of formula I in the presence of NH₄Cl and AcOH,
- e) optionally converting the compound of formula I thus obtained into another compound of formula II.

14. (previously presented) A compound of formula



in which:

- R₁ is chosen from hydrogen, halogens, a nitro group and groups -NR₈R₉ in which R₈ and R₉ are chosen, independently of each other, from hydrogen and (C₁-C₄) alkyl groups,
- R₂ is chosen from hydrogen and halogens,

- R_3 is chosen from halogens, (C_1-C_4) alkyl groups, (C_1-C_6) alkoxy groups, a guanidino group, groups $-NR_{10}R_{11}$ in which R_{10} and R_{11} are chosen, independently of each other, from hydrogen, (C_1-C_4) alkyl groups, (C_1-C_4) phenylalkyl groups and groups $-(CH_2)_n-Y$ with Y being chosen from halogens and CN , $-CH(O-Et)_2$, (C_1-C_6) alkoxy, $-O-(CH_2)_2-N(CH_3)_2$ and $-N(CH_3)_2$ groups and $n = 1$ to 3 ,

- R_4 is chosen from hydrogen, halogens, nitro groups and groups $-NR_{12}R_{13}$ in which R_{12} and R_{13} are chosen, independently of each other, from hydrogen and (C_1-C_4) alkyl groups,


- R_5 , R_6 and R_7 are chosen from:

hydrogen or a halogen atom,

C_1-C_6 alkyl, hydroxyl, C_1-C_6 alkoxy, (C_1-C_6) alkoxy(C_1-C_6) alkyl, (C_1-C_4) alkylcarbonyloxy(C_1-C_4) alkyl, $-CHO$, $-COOH$, $-CN$, $-CO_2R_{14}$, $-CONHR_{14}$ and $-CONR_{14}R_{15}$ groups, $-NHCOR_{14}$ and $-NR_{14}R_{15}$ in which R_{14} and R_{15} are chosen, independently of each other, from hydrogen and (C_1-C_6) alkyl, $-phenyl-CO-CH_3$ and $-CH_2-CH_2-N(CH_3)_2$ groups,

$-phenyl-CO-CH_3$ or $-phenyl-CO-CH=CH-N(CH_3)_2$, morpholino, nitro or SO_3H groups,

groups:



R_{16} and R_{17} being chosen from C_1-C_6 alkyl groups and Ar being a C_6-C_{14} aryl group,

with the exclusion of compounds in which either R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 = H, or R_1 , R_3 , R_4 , R_5 , R_6 , R_7 = H and R_2 = Br, or R_1 , R_2 , R_4 , R_5 , R_6 , R_7 = H and R_3 = OCH_3 , or R_1 , R_2 , R_3 , R_4 , R_6 , R_7 = H and R_5 = OH or OCH_3 or R_1 = NO_2 and R_2 , R_3 , R_4 , R_5 , R_6 , R_7 = H, and the addition salts of these compounds with pharmaceutically acceptable acids.